Skip to main content

Table 1 HER2 is amplified in all PAM50 subtypes, and enriched in HER2E

From: HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors

Subtype

TCGA (n = 106)

Metabric (n = 133)

USO1062 (n = 79)

HER2E

48 (45%)

71 (53%)

30 (38%)

Luminal A

19 (18%)

14 (11%)

26 (33%)

Luminal B

32 (30%)

27 (20%)

17 (21%)

Basal-like

7 (7%)

21 (16%)

6 (8%)

  1. Number and percentage of human epidermal growth factor receptor 2 amplified (HER2A) tumors across the prediction analysis of microarray 50 (PAM50) subtypes in The Cancer Genome Atlas (TCGA), Metabric and the USO1062 clinical trial. HER2E HER2-enriched
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us